CD40LG and neoplasm: In summary, we showed that greater peak anti-GH IgM levels were associated with longer PFS of patients, similar to the significant correlation of higher anti-GH IgG levels with better PFS, as we previously reported.5 Moreover, our findings suggest the potential value of anti-GH IgM ≥1:320 within first 4 weeks and higher GH expression on tumor in selecting patients who are likely to benefit from AS/OBI-821 in the future, if confirmed in the ongoing global phase III trial of AS/OBI-821.